The immune system has an important ability to differentiate between normal cells in the body from those it sees as "foreign." This helps the immune system attack foreign cells without harming the normal cells by using "checkpoints." Immune checkpoints are molecules on specific immune cells that must be activated (or inactivated) to start an immune response. Cancer cells use these checkpoints to avoid immune system attacks on them. Certain drugs that target these checkpoints are called checkpoint inhibitors. These drugs target cell surface checkpoint proteins to stimulate the recognition and destruction of cancer cells by the immune system. PD-1 is a checkpoint protein on immune cells called T cells. Programmed cell death protein 1(PD-1) inhibitors are a group of checkpoint inhibitor anticancer drugs that block the activity of PD-1 immune checkpoint proteins present on the surface of cells. Anti-PD-1 monoclonal antibodies block the PD-1 receptor, so the T cells are no longer inhibited and activate the immune response against the tumor.
MARKET SCOPE
The "Global Anti-PD-1 MAb Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the anti-PD-1 MAb market with detailed market segmentation by product, application, and geography. The report provides key statistics on the market status of the leading anti-PD-1 MAb market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
-Based on product, the global anti-PD-1 MAb market is segmented into 40mg, 100mg, 200mg and others.
-On the basis of application, the market is bifurcated into melanoma patients, lung cancer patients, lymphoma patients and other.
MARKET DYNAMICS
Drivers
-The increasing prevalence of cancer and growing awareness of checkpoint inhibitors drive the anti-PD-1 MAb market.
-The rising adoption of pembrolizumab and nivolumab and increasing geriatric population boost the market growth.
-Technological advancements in screening procedures for cancer, rising healthcare expenditures, and growing government initiatives to alleviate cancer fuel the market growth.
Restraints
-High cost associated with research activities.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The anti-PD-1 MAb market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the anti-PD-1 MAb market in these regions.
IMPACT OF COVID-19 ON ANTI-PD-1 MAB MARKET
COVID-19 first began in Wuhan (China) during December 2019, and since then, it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, UK, Turkey, Italy, and Spain are some of the worst affected countries in terms of confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Cancer patients are considered a high-risk group for COVID-19. Moreover, the increased burden on the healthcare industry concerning isolation, prevention, and providing treatment to infected patients resulted in elective surgeries being postponed. Therefore, the most significant risk for cancer patients is the unavailability of the usually high-level medical services, as all the hospital resources, in terms of structures, tools, and healthcare professionals, are dedicated to outbreak management. Hence, the factors mentioned above have widely affected the growth of the market during this pandemic.
MARKET PLAYERS
The report covers key developments in the anti-PD-1 MAb market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market players from anti-PD-1 MAb market are anticipated to have lucrative growth opportunities in the future with the rising demand for anti-PD-1 MAb in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the anti-PD-1 MAb market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
-Merck
-Junshi Pharma
-Coherus BioSciences
-Bristol Myers Squibb
-TopAlliance Biosciences Co., Ltd.
-Selleck Chemicals
-Aditya Pharma
-Beijing Beigene
-Genentech
-Innovent Biologics Inc
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.